Fang-yi Fan

Dr. Fang-yi Fan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Tissue and Cell
Verified
Journal Article
Open access
LQLing Qiu
Ling Qiu
JCJiao Cai
Jiao Cai
NZNan Zhang
Nan Zhang
LMLei Ma
Lei Ma
FFFang-yi Fan
Fang-yi Fan
XLXiaoming Li
Xiaoming Li
Although microRNAs (miRNAs) exert an important role in the osteogenesis of mesenchymal stem cells (MSCs), the effect of miR-381-3p on the osteogenic differentiation in MBD‑MSCs is still unclear. The BMMSCs from patients with MBD (MBD‑MSC) or normal participants (Normal‑MSC) were isolated and induced to differentiation with dexamethasone. BMMSCs were transfected with miR-381-3p mimic, miR-381-3p inhibitor, and FGF7 siRNA to regulate the expression of miR-381-3p or FGF7. The direct binding between miR-381-3p and FGF7 was predicted and confirmed by bioinformatics prediction and luciferase reporter assay. The effect of miR-381-3p on the osteogenic differentiation of BMMSCs was assessed by RT‑qPCR, alizarin Red S staining and western blot assays. Isolated BMMSCs showed the regular morphology, and were positive for CD44, CD90 and CD105 but negative for CD34 and CD45 markers. The calcium deposition and the relative mRNA expression levels of ALP, OC and OPN after induction were markedly enhanced. MiR-381-3p was upregulated in BMMSCs. Also, inhibition of miR-381-3p notably promoted osteogenic differentiation, vice versa. Besides, miR-381-3p could directly target FGF7 and negatively modulate the expression of FGF7. Moreover, inhibition of FGF7 attenuated the increase of the calcium deposition, and the relative mRNA expression of ALP, OC and OPN caused by the downregulation of miR-381-3p. In addition, the miR-381-3p inhibitor-induced the enhancement of the relative protein expressions of FGFR2, p-MEK and p-ERK1/2 were significantly reduced by the co-transfection of si-FGF7. Furthermore, the application of LY3214996, the inhibitor of ERK also verified these outcomes. MiR-381-3p directly targeting FGF7 modulated the osteogenic differentiation via MEK/ERK signaling pathway in BMMSCs.

3 January 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
BDBaitao Dou
Baitao Dou
SRShihui Ren
Shihui Ren
LQLing Qiu
Ling Qiu
XZXupai Zhang
Xupai Zhang
NZNan Zhang
Nan Zhang
FFFang-yi Fan
Fang-yi Fan
Background: Chimeric antigen receptor T (CAR-T) cell immunotherapy is becoming one of the most promising treatments for hematological malignancies, however, complications such as cytokine release syndrome (CRS) seriously threaten the lives of patients. Interleukin 6(IL-6) monoclonal antibody is the common and useful treatment of CRS, however, it is not clear whether prophylactic use IL-6 monoclonal antibody before CAR-T therapy can reduce the incidence of CRS.Purpose: This study aims to systematically evaluate whether the prophylactic use of IL-6 monoclonal antibody can reduce the incidence of CRS.Data sources and methods: We searched the PubMed, Embase, web of Science, and Cochrane Library databases for studies that reported the prophylactic use of IL-6 monoclonal antibody in the treatment of CRS-related complications of CAR-T cell immunotherapy before December 2022. The literature is screened according to the established inclusion and exclusion criteria, relevant data are extracted, and the quality of the literature is evaluated using the scale Cochrane bias risk assessment tool, and the Review Manager 5.3 is used to draw for related charts. Since the two experimental data only provide the median, the maximum and minimum values of the data, the mean and standard (Standard Deviation, SD) are calculated by this document Delai, and finally use Review Manager for data processing, and STATA software for supplementation.Results: A total of 2 trials with a total of 37 participants were included in this study. Meta-analysis showed that compared with no use of IL-6 monoclonal antibody to prevent CRS, IL-6 monoclonal antibody was given to patients at 8 mg/kg one hour before CAR-T cell infusion, which reduced the incidence of CRS [RR: 0.41 95% confidence interval (0.20, 0.86) I[2] = 0.0% P = 0.338 z = −2.369 (p = 0.018)]. In subgroup analysis, compared with those who did not use IL-6 monoclonal antibody to prevent CRS, IL-6 monoclonal antibody was given to patients at 8 mg/kg one hour before CAR-T cell infusion, which reduced lactate dehydrogenase (LDH)[MD: −617.21, 95% confidence interval (−1104.41, −130.01) I[2] = 0% P = 0.88 Z = 2.48 (P = 0.01)], prophylactic use of IL-6 monoclonal antibody has a significant effect on reducing peak C-reactive protein (CRP) after CAR-T therapy [MD: −11.58, 95% confidence interval (−15.28, −7.88) I[2] = 0.0% P = 0.73 z = 6.14 (p < 0.00001)].Conclusion: The prophylactic use of IL-6 monoclonal antibody can significantly reduce the incidence of CRS complications after CAR-T therapy, can also reduce LDH vaule and peak CRP vaule after CAR-T therapy.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023487662, identifier CRD42023487662.

31 May 2020 in BMB Reports
Verified
Journal Article
Open access
PDF file
NZNan Zhang
Nan Zhang
LQLing Qiu
Ling Qiu
TLTao Li
Tao Li
XWXiao Wang
Xiao Wang
RDRui Deng
Rui Deng
FFFang-yi Fan
Fang-yi Fan
Nan Zhang, Ling Qiu, Tao Li, Xiao Wang, Rui Deng, Hai Yi, Yi Su & Fang-yi Fan. BMB Reports 2020;53:254-9. https://doi.org/10.5483/BMBRep.2020.53.5.219

3 December 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
JCJiao Cai
Jiao Cai
LQLing Qiu
Ling Qiu
LMLei Ma
Lei Ma
NZNan Zhang
Nan Zhang
FFFang-yi Fan
Fang-yi Fan
The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.

1 August 2025 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
BDBai-Tao Dou
Bai-Tao Dou
MLMeng-Jiao Li
Meng-Jiao Li
YLYan-Ling Li
Yan-Ling Li
DCDan Chen
Dan Chen
CYChengwei Yang
Chengwei Yang
HYHao Yao
Hao Yao
Acute high-altitude illness (AHAI), triggered by hypobaric hypoxia following rapid ascent to high elevations, induces complex pathophysiological responses that may be life-threatening. Recent advances in regenerative medicine have highlighted the therapeutic potential of stem cells in mitigating hypoxia-induced damage. Among them, Mesenchymal stem cells (MSCs), the most extensively investigated, exert therapeutic efficacy through immunomodulation, attenuation of oxidative stress, and enhancement of tissue repair mechanisms. Their paracrine signaling profile facilitates angiogenesis and stabilization of the hypoxic microenvironment. Neural stem cells (NSCs) exhibit robust proliferation and differentiation under hypoxic conditions, offering a novel avenue for the treatment of high-altitude cerebral pathology. Additionally, induced pluripotent stem cells (iPSCs), with their pluripotency and patient-specific derivation, present significant promise for personalized, cell-based interventions. Experimental studies demonstrate that these stem cell types modulate the hypoxic milieu via secretion of cytokines, remodeling of the immune microenvironment, and promotion of neovascularization. Nonetheless, several translational challenges persist, including suboptimal homing efficiency, potential immunogenicity, and uncertain long-term safety profiles in high-altitude settings. Future research should prioritize elucidation of stem cell behavior in hypobaric hypoxia, optimization of delivery systems, and establishment of standardized therapeutic protocols. Rigorous clinical validation through evidence-based approaches will be essential to substantiate safety and efficacy. With continued advances in stem cell biology and translational techniques, stem cell-based therapy is poised to emerge as a viable strategy for the prevention and management of AHAI, provided that its clinical deployment is underpinned by robust scientific evidence.

6 October 2023 in Medicine
Verified
Journal Article
Open access
NZNan Zhang
Nan Zhang
SZShan Bm Zhang
Shan Bm Zhang
LMLei Mm Ma
Lei Mm Ma
LQLing Mm Qiu
Ling Mm Qiu
QMQing-Li Bm Meng
Qing-Li Bm Meng
FFFang-yi Fan
Fang-yi Fan
Rationale: Subcutaneous panniculitis like T-cell lymphoma (SPTCL) is a rare primary cutaneous lymphoma that belongs to peripheral T cell lymphomas, of which the overall prognosis is poor. Chidamide, a deacetylase inhibitor, has been approved for the treatment of peripheral T cell lymphomas. However, due to the rare occurrence of SPTCL, it is currently unknown whether Chidamide is effective for all SPTCL patients and whether there are molecular markers that can predict its therapeutic effect on SPTCL. Patient concerns and diagnoses: The patient was a sixteen-year-old male and underwent subcutaneous nodule biopsy which showed SPTCL. Next-generation sequencing revealed AT-rich interaction domain 1A (ARID1A) mutation, and positron emission tomography/computed tomography showed scattered subcutaneous fluorodeoxyglucose metabolic lesions throughout the body. Interventions and outcomes: During the first 3 CHOP (cyclophosphamide, doxorubicin, vindesine, and prednisone) treatment, the patient relapsed again after remission, and the successive addition of methotrexate and cyclosporine did not make the patient relapsing again. Then, after adding Chidamide to the last 3 CHOP treatment, the patient was relieved again. The patient underwent autologous hematopoietic stem cell transplantation (auto-HSCT) after completing a total of 8 cycles of chemotherapy, and continued maintenance therapy with Chidamide after auto-HSCT. Currently, the patient has been in continuous remission for 35 months. Lessons subsections: This case is the first report of a refractory/recurrent SPTCL with ARID1A mutation treated with Chidamide. The treatment of Chidamide on the basis of CHOP plus auto-HSCT therapy achieved good results, suggesting that ARID1A may act as a molecular marker to predict the therapeutic effect of Chidamide on SPTCL patients, which helps to improve the precision of SPTCL treatment and the overall prognosis of SPTCL patients.